YD Bio Ltd YDES
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.10
- Day Range
- $6.09–6.42
- 52-Week Range
- $1.92–22.00
- Bid/Ask
- $6.16 / $6.40
- Shares Outstanding
- 70.84M
- Market Cap
- $449.14M
- Volume/Avg
- 14,845 / 280,997
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 298.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
- Website
- https://www.ydesgroup.com
Valuation
|
Metric
|
YDES
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 96.59 |
Price/Sales | 298.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
YDES
|
|---|---|
Quick Ratio | 3.01 |
Current Ratio | 5.23 |
Interest Coverage | — |
Quick Ratio
YDES
Profitability
|
Metric
|
YDES
|
|---|---|
Return on Assets (Normalized) | −64.33% |
Return on Equity (Normalized) | −284.72% |
Return on Invested Capital (Normalized) | −288.61% |
Return on Assets
YDES
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#RL&C%! | LOCK|h?!> | $123B | |||
| Moderna Inc
MRNA
| LOCK|j#>#R!& | LOCK|P$ | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^Xx^>f | LOCK|hZ&w | $78B | |||
| argenx SE ADR
ARGX
| LOCK|>&X<GR | LOCK|?B | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bvp&?w< | LOCK|qzC | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PFTYH% | LOCK|k@x$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?cG^vhp | LOCK|TYJ%x | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|HV<>bp | LOCK|T< | $22B | |||
| Incyte Corp
INCY
| LOCK|lV<<l$H | LOCK|%P | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|C&#c&@ | LOCK|!@M | $14B |
United States